Digest Network Come funziona
Network
/
Società
Al
Non verificato

Alnylam Pharmaceuticals, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteWeb e Social Network

27 comunicati stampa

Guarda tutti i comunicati
01/04/2025
Eventi
Web e Social Network
Biotecnologia
Farmaceutica
Salute
Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare Conference
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1,00
0
29/03/2025
Eventi
Industria
Igiene alimentare
Biotecnologia
Medicina - Varie
Cardiologia
Sanità
Farmaceutica
Salute
Oncologia
Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology’s Annual Scientific Session 2025
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1,00
0
28/03/2025
Industria
Biotecnologia
Farmaceutica
Salute
FDA Approves Qfitlia™ (fitusiran), the First siRNA (RNAi Therapeutic) for the Treatment of Hemophilia A or B
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1,00
0
20/03/2025
Multimedialità
Web e Social Network
Telefonia e Varie
Industria
Eventi
Salute
Igiene alimentare
Medicina - Varie
Farmaceutica
Cardiologia
Biotecnologia
Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1,00
0
11/03/2025
Web e Social Network
Eventi
Industria
Salute
Biotecnologia
Scienza
Farmaceutica
Alnylam to Webcast Presentation at Stifel 2025 Virtual CNS Forum
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1,00
0
05/03/2025
Mercato del lavoro
Salute
Biotecnologia
Scienza
Farmaceutica
Alnylam Announces Retirement of Longtime Board Member, Dr. Phillip A. Sharp, Company Co-Founder and Industry Luminary
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1,00
0
25/02/2025
Biotecnologia
Sanità
Salute
Farmaceutica
Medicina - Varie
Industria
Alnylam Highlights Significant Pipeline Progress and Platform Innovation at R&D Day
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1,00
0
13/02/2025
Biotecnologia
Igiene alimentare
Salute
Farmaceutica
Web e Social Network
Telefonia e Varie
Mercato azionario
Eventi
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Period Progress
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1,00
0
27/11/2024
Eventi
Web e Social Network
Biotecnologia
Farmaceutica
Salute
Alnylam to Webcast Presentation at Piper Sandler 36th Annual Healthcare Conference
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1,00
0
25/11/2024
Industria
Scienza
Cardiologia
Biotecnologia
Farmaceutica
Salute
Igiene alimentare
Medicina - Varie
Alnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1,00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0